Centuple Global Ltd
₹34.10▲ +1.39 (+4.25%)
CENTUPLE·BSE·Healthcare
Market Cap
14.32 Cr
PE Ratio
568.33
Volume
1,189
Day High - Low
34.10 - 31.13
52W High-Low
144.40 - 28.42
₹34.10▲ +1.39 (+4.25%)
Market Cap14.32 Cr
PE Ratio568.33
Volume1,189
Day High - Low34.10 - 31.13
52W High-Low144.40 - 28.42
Centuple Global Ltd (CENTUPLE): company summary
The company's business has grown dramatically, with annual revenue surging 114662.0% to ₹574 crore and annual net profit jumping 4933.3% to ₹2 crore.
Centuple Global Ltd (CENTUPLE) is a micro-cap Healthcare company valued at ₹14 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- Centuple Global Ltd last traded at ₹34.1, up 4.25% on the day.
- Recent developments
- 2026-06-30: The company reported zero revenue and a net loss of ₹0 crore for the latest quarter, marking a sharp decline from the ₹12 crore revenue and ₹0 crore profit in the same quarter a year earlier. 2026-03-31: Revenue was ₹279 crore with a net loss of ₹0 crore, showing a slight improvement from the ₹174 crore revenue and ₹1 crore profit in the prior quarter.
- Financial performance
- The company's business has grown dramatically, with annual revenue surging 114662.0% to ₹574 crore and annual net profit jumping 4933.3% to ₹2 crore. However, the net profit margin has fallen sharply to 0.3% from 5.1% in the prior year. The latest quarter saw revenue drop 100.0% to ₹0 crore and net profit swing to a loss of ₹0 crore from a profit of ₹0 crore in the same quarter a year earlier.
- Valuation multiples
- The stock trades at 568.3 times earnings, a premium to the Healthcare median of 32.0, 0.85 times book value.
- Things to watch
- The company has a high debt to equity ratio of 3.26, indicating significant leverage. The net profit margin has dropped 4.8 percentage points to 0.3%, and the latest quarter saw a net loss of ₹0 crore, despite a revenue drop of 100.0% compared to the same quarter a year earlier. The stock is 77.3% below its 52-week high.
- Where it stands
- The company has experienced explosive revenue growth, but its net profit margin has collapsed and recent quarters show a loss despite a revenue drop. The stock is 77.3% below its 52-week high, and the company has a high debt to equity ratio of 3.26. The latest quarter ended with a net loss of ₹0 crore.
Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.2/10
Weak
Fair Value
Sign in to see
ROE
72.98%
Strong
P/E
568.33x
Expensive
Debt / Equity
3.26
High
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹31.13
₹34.10
52W₹28.42
₹144.40
DocStoX take
Supported by growth (9.0), but held back by momentum (0.0). Growth looks strong at 9.0, but that is offset by momentum at 0.0 and risk at 2.1. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.2
/10
Weak
Quality
Modest
ROE 73.0%
Valuation
Fair
P/E 200.0×
Growth
Strong
Revenue +731.0% 3Y CAGR
Risk
High risk
D/E 3.26
Momentum
Weak
5% of 52-week range
At a glance
Market Cap
₹14 Cr
52W High / Low
₹144 / ₹28
Dividend Yield
0.00%
Promoter Holding
0.00%
EPS (TTM)
₹0.06
Book Value
₹3.78
Key highlights
- Revenue compounding 731% a year
- Strong returns on equity (73%)
- Capital works hard — ROCE 26%
- High leverage — debt is 3.3× equity
- Loss-making in some of the last 5 years
3 Positives4 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore Centuple Global Ltd’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
Centuple Global Ltd peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
SUN PHARMACEUTICAL IND LDIVI S LABORATORIES LTDTORRENT PHARMACEUTICALS LLAURUS LABS LIMITEDZYDUS LIFESCIENCES LTDAPOLLO HOSPITALS ENTER. LCIPLA LTDDR. REDDY S LABORATORIESAUROBINDO PHARMA LTDMANKIND PHARMA LIMITEDLUPIN LIMITEDMANIPAL HEALTH ENTERPRI L
Compare Centuple Global Ltd with peers
Related tools & concepts
Value Centuple Global Ltd with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing